Polyphor AG
- ISIN: CH0106213793
- Land: Schweiz
Nachricht vom 14.10.2020 | 07:30
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
Polyphor AG / Key word(s): Agreement/Financing Allschwil, Switzerland, October 14, 2020 Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program Polyphor AG (SIX: POLN), announced today that it has received a new and second non-dilutive funding award from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership led by Boston University dedicated to supporting the development of antibacterial products, to diagnose, prevent and treat drug-resistant infections. This award will support the development of the "thanatin derivatives program" belonging to Polyphor's novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria. CARB-X will provide Polyphor with initial funding of up to USD 2.62 million to complete the hit-to-lead stage and up to USD 15.82 million if certain project milestones are met. This funding is the second major support for Polyphor's antibiotics program and follows a previous grant in 2019. "CARB-X fosters the best science and most promising early development R&D-projects in the world. This award provides further support to our research efforts in progressing a new class of antibiotics to combat antimicrobial resistance, one of the greatest global challenges for healthcare," said Gokhan Batur, Chief Executive Officer of Polyphor. "This second award is a strong validation of our innovative antibiotic platform and an important milestone in the implementation of our renewed strategy in this field presented earlier this year, and we would like to thank CARB-X for their ongoing trust and support." The thanatin-derivative antibiotics discovered by Polyphor and the University of Zurich are part of Polyphor's new Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics and target the lipopolysaccharide (LPS) transport protein A (LptA), a novel essential target in the LPS transport mechanism of Gram-negative bacteria. Most importantly, these new types of antibiotics show potent and specific antimicrobial activity against Enterobacteriaceae, including extremely drug resistant strains, which are among the WHO priority-1 pathogens. "Serious infections are a global health threat, due in part to the emergence of drug-resistant bacteria for which we do not have therapies," said Erin Duffy, R&D Chief of CARB-X. "Polyphor's project enriches the pool of novel approaches to deliver a therapeutic that can treat infections caused by multidrug-resistant Gram-negative pathogens for which we have few options. It is in the early stages of development, and if successful and approved, it could potentially change the way these life-threatening infections are treated and save lives." For further information please contact: For Investors: For Media: About Polyphor About CARB-X Disclaimer This research is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from Wellcome Trust and Germany's Federal Ministry of Education and Research (BMBF). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Office of the Assistant Secretary for Preparedness and Response, or other CARB-X funders. End of ad hoc announcement |
Language: | English |
Company: | Polyphor AG |
Hegenheimermattweg 125 | |
4123 Allschwil | |
Switzerland | |
Phone: | +41 61 567 1600 |
Fax: | +41 61 567 1601 |
E-mail: | info@polyphor.com |
Internet: | www.polyphor.com |
ISIN: | CH0106213793 |
Valor: | POLN |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1140592 |
End of Announcement | EQS Group News Service |
Interaktiv
Weblinks
GBC-Fokusbox

Northern Data: "Waren zum richtigen Zeitpunkt mit dem richtigen Konzept am Markt"
Kryptowährungen, allen voran Bitcoin, sind zuletzt mit deutlichen Steigerungen wieder in den Investorenfokus gerückt. Northern Data, ein Spezialist für High Performance Computing, zählt laut eigenen Angaben zu den weltweit führenden Anbietern für Infrastruktur im Bereich Bitcoin-Mining. Wir haben mit dem Gründer und CEO Aroosh Thillainathan über die Perspektiven für Bitcoin und die Wachstumsaussichten für die Northern Data gesprochen.
Der AKTIONÄR News

25. Januar 21:55 Schlussglocke: Dow Jones kaum bewegt - Apple glänzt, Wahnsinn um ...
25. Januar 21:46 CureVac mit Kapitalerhöhung - Aktie unter Druck - die Details
25. Januar 20:51 Amazon, Alibaba und wer noch? Das sind die Top-Picks der Citigroup
25. Januar 19:52 Linde: Mehr Dividende plus Aktienrückkauf - folgt jetzt das ...
25. Januar 19:30 Tesla, General Motors und Co: 5 Möglichkeiten, wie Joe Biden die ...
News im Fokus

Linde plc: Linde Declares Dividend Increase for 2021
25. Januar 2021, 20:09